Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions-Reference-Cited by-同舟云学术

Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions

Published:2019-05 Issue:5 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Khalilieh Sauzanne G.¹,Yee Ka Lai¹,Sanchez Rosa I.¹,Fan Li¹,Anderson Matt S.¹,Sura Monali¹,Laethem Tine¹,Rasmussen Scott²,van Bortel Luc³,van Lancker Griet³,Iwamoto Marian¹

Affiliation:

1. Merck & Co., Inc., Kenilworth, New Jersey, USA

2. IQVIA, Overland Park, Kansas, USA

3. Department of Pharmacology, Ghent University, Ghent, Belgium

Abstract

Identifying and understanding potential drug-drug interactions (DDIs) are vital for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. This article discusses DDIs between doravirine, a nonnucleoside reverse transcriptase inhibitor (NNRTI), and cytochrome P450 3A (CYP3A) substrates and drugs that modulate CYP3A activity.

Funder

Merck

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02016-18

Reference69 articles.

1. Insurability of HIV-positive people treated with antiretroviral therapy in Europe

2. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies

3. Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study